Lincoln Pharmaceuticals growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+7.7%+7.4%+13.8%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−3.8%+1.6%+12.0%
−6.1%−0.8%+11.6%
+6.7%−11.7%+28.0%
+6.7%−11.7%+28.0%
+11.7%+13.8%+19.2%
+12.8%+13.3%+18.0%
+14.3%+47.1%+61.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

LINCOLN₹507.90

Lincoln Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersSIGACHITHEMISMEDBAJAJHCAREAMRUTANJANJAGSNPHARMWANBURYAHCLMcap ₹1,017 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+13.8+7.4+7.7—
EBITDA Growth—+12.0+1.6-3.8—
EBIT Growth—+11.6-0.8-6.1—
Net Income Growth—+28.0-11.7+6.7—
EPS Growth—+28.0-11.7+6.7—
Total Assets Growth—+19.2+13.8+11.7—
Total Equity Growth—+18.0+13.3+12.8—
Cash from Operations Growth—+61.0+47.1+14.3—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.